1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Murren J, Ganpule S, Papac R, Son Y, Peschel R, Durivage H, Buzaid A, Lamb L, Makuch R, Hait W. A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 1993, 5: 53-7. PMID: 8395915.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerMedian survival timeMitomycin CComplete respondersLung cancerSurvival timeUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerUnresectable non-small cell lung cancerDay 1Concurrent mitomycin CPhase II trialOverall response rateX-irradiationModerate stomatitisSustained remissionII trialSplit courseWeek restMedian durationContinuous infusionSimultaneous administrationRadiation therapyResponse rate
1989
Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 Infection
Scott G, Hutto C, Makuch R, Mastrucci M, O'Connor T, Mitchell C, Trapido E, Parks W. Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 Infection. New England Journal Of Medicine 1989, 321: 1791-1796. PMID: 2594038, DOI: 10.1056/nejm198912283212604.Peer-Reviewed Original ResearchConceptsMedian survivalMedian ageHuman immunodeficiency virus type 1 (HIV-1) infectionHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Common first manifestationLymphoid interstitial pneumoniaIntravenous drug useProportional hazards analysisTime of diagnosisPneumocystis carinii pneumoniaHIV-1 infectionMedian survival timeType 1 infectionRecurrent bacterial infectionsJackson Memorial HospitalLong-term survivalYears of ageVirus type 1Candida esophagitisProgressive diseaseAntiviral treatmentBlood transfusionInterstitial pneumonia